Evaxion Biotech Has Entered Into An Option And License Agreement With Merck For Two Preclinical Vaccine Candidates, For An Upfront Payment Of $3.2M And Up To $10M In 2025, If Merck Exercises Its Option To License Either One Or Both Candidates And...
Evaxion Biotech Has Entered Into An Option And License Agreement With Merck For Two Preclinical Vaccine Candidates, For An Upfront Payment Of $3.2M And Up To $10M In 2025, If Merck Exercises Its Option To License Either One Or Both Candidates And...
Evaxion生物科技已与默沙东签订了一项期权和许可协议，涉及两个处于临床前阶段的疫苗候选者，预付款320万美元，2025年最高可达1亿美元，如果默沙东选择行使其对其中一个或两个候选者的许可权，
Evaxion Biotech Has Entered Into An Option And License Agreement With Merck For Two Preclinical Vaccine Candidates, For An Upfront Payment Of $3.2M And Up To $10M In 2025, If Merck Exercises Its Option To License Either One Or Both Candidates And Milestone Payments Of Up To $592M Per Product
Evaxion生物科技已与默沙东签订了一项期权和许可协议，涉及两个临床前生物-疫苗候选者，首付款为320万美元，2025年默沙东行使其许可期权时，可达到1000万美元，每种产品的里程碑支付可高达59200万美元
Under the terms of the agreement, Evaxion has granted MSD an option to exclusively license Evaxion's preclinical vaccine candidates EVX-B2 and EVX-B3. EVX-B2 is a protein-based candidate for Gonorrhea and EVX-B3 targets an undisclosed infectious agent.
根据协议条款，Evaxion已授予默克一个独家许可期权，以独家许可Evaxion的临床前疫苗候选者EVX-B2和EVX-B3。 EVX-B2是一种基于蛋白质的淋病候选者，而EVX-B3针对一种未透露的传染病原体。
资讯热榜
更新时间